neflamapimod
Small molecule
Evidence outlook · lead readout
RewinD-LB (NCT05869669) · Dementia With Lewy Bodies
The lead readout missed its primary endpoint. The grade and rationale below record what the trial was designed to show and what it found.
RewinD-LB (NCT05869669): The blinded treatment period was randomized, quadruple-masked, placebo-controlled, and included 159 participants (79 assigned to neflamapimod and 80 to placebo). Its clinical primary endpoint was not met: the difference in CDR-SB change was 0.01 points, with p=0.9448.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
RewinD-LB NCT05869669 · Dementia With Lewy Bodies The blinded treatment period was randomized, quadruple-masked, placebo-controlled, and included 159 participants (79 assigned to neflamapimod and 80 to placebo). Its clinical primary endpoint was not met: the difference in CDR-SB change was 0.01 points, with p=0.9448. Registry: NCT05869669 | 2 | Change in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) in Neflamapimod-treated Participants Compared to Placebo Recipients (Blinded Treatment Period) (16 weeks) 2025-05-29 | Change in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) in Neflamapimod-treated Participants Compared to Placebo Recipients (Blinded Treatment Period) (16 weeks): Neflamapimod 0.36 Scores on a scale (Standard Error 0.193) | Placebo 0.34 Scores on a scale (Standard Error 0.188) | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (10)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Dementia with Lewy Bodies: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Neflamapimod: this drug | Phase 2 | Small molecule | p38-alpha MAPK | Partial signal | NCT05869669: Change in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) in Neflamapimod-treated Participants Compared to Placebo Recipients (Blinded Treatment Period) (16 weeks): Neflamapimod 0.36 Scores on a scale (Standard Error 0.193) | Placebo 0.34 Scores on a scale (Standard Error 0.188) missed | |
| Zervimesine | Phase 2 | Small molecule | Sigma-2 receptor complex | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.